Skip to Content



NCI has a memorandum of understanding with Europe’s Affinomics Consortium to facilitate coordination and avoid duplication in the production of cancer-associated proteins and affinity reagents, and the subsequent characterization with public dissemination of products and data to the research community. Euorpe’s Affinomics Consortium is focused on generating comprehensive binder sets for protein kinases, protein tyrosine phosphatases, SH2 domain containing proteins, and cancer associated proteins, including those with somatic or germ line mutations in cancer.

Antibody Characterization Laboratory (SAIC - Frederick, NCI Frederick)

The Antibody Characterization Lab (ACL) thoroughly characterizes monoclonal antibodies or other renewable affinity binding reagents for use in cancer related research. All antibodies are characterized (not exclusive list) using ELISA, Western blot (recombinant/cell lysate/native), Surface Plasmon Resonance (SPR), SPR pairing, Immuno Mass Spectroscopy, Reverse Phase Protein Array, Immuno Histochemistry (IHC). Data and Standard Operating Procedures (SOPs) are all made available on the web including both methods that give positive and negative methods. It is the broad range of specialized assays and the use of standardized methods that are made available to researchers that make this a unique resource. The ACL also has access to the NCI60 cell lines that are a unique resource not widely available to outside firms. The availability of the data and methods allows researchers to select appropriate antibodies for their particular use and provides researchers with tools to quality control materials for experiments. All materials are freely available to the research community along with all of the characterization data and SOPs used to generate the data.

Argonne National Laboratories (ANL)

NCI had an Interagency Agreement with ANL to produce ~200 cancer-related proteins for use in antibody production, affinity capture technology development, and creation of reagent protein standards. In addition, a "Protein ID-to-Antibody Production" Workflow was used that began with protein target acquisition and used publicly available clones/expression vectors to produce proteins, which were then characterized and their data submitted to a public database. These proteins were used for a variety of purposes, including antigen development, proteomics platform assessment, and standards development.

Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa

The University of Iowa's Developmental Studies Hybridoma Bank (DSHB) distributes all hybridomas and monoclonal antibodies from NCI's Clinical Proteomic Technologies for Cancer programs (CPTC). The DSHB was established to supply investigators with monoclonal antibodies useful for studies in developmental and cell biology, which may be ordered as tissue culture supernatants, ascites, or concentrate; selected hybridomas are also available as frozen or growing cells.

DNASU Plasmid Repository of the Biodesign Institute at Arizona State University (DNASU)

The DNASU Plasmid Repository of the Biodesign Institute at Arizona State University (DNASU) serves as central repository for plasmid clone collections and distribution. DNASU currently stores and distributes nearly 100,000 plasmids including over 35,000 human and mouse plasmids, full genome collections of numerous organisms, the protein expression plasmids from the Protein Structure Initiative Material Repository (PSI-MR), and both small and large collections from individual researchers. Additionally this institution serves as a repository for CPTC plasmid clone collections and distribution.


Epitomics, has signed a Material Cooperative Research and Development Agreement (M-CRADA) with SAIC-Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) and in coordination with the Office of Cancer Clinical Proteomics Research. Under the M-CRADA, the NCI will characterize renewable antibodies from Epitomics, Inc. that are associated with putative cancer targets. Characterization assays along with SOPs will be according to the CPTC antibody characterization program. The antibodies and the characterization data collected will be made available to the research community in an effort to advance biomedical discoveries.

Human Protein Atlas (HPA)

After monoclonal antibodies produced from the Clinical Proteomic Technologies for Cancer programs are first characterized by the ACL at NCI-Frederick, they are further characterized using tissue microarrays at the Human Protein Atlas (HPA). The HPA is a well-recognized, mature resource for tissue microarray analysis expression data for thousands of antibodies across hundreds of normal human tissues and cancer cells. The data is publicly available and presented as high-resolution images of immunohistochemically stained tissues and cell lines annotated with links to proteins for specific genes or by browsing individual chromosomes. To learn more about the Human Protein Atlas, visit:


Millipore distributes a subset of the CPTC antibodies to the research community. These antibodies are designated with CPTC prefix and characterization data is available from both Millipore and CPTC.

Structural Genomics Consortium

The SGC Toronto/Canada (Structural Genomics Consortium) is a not-for-profit, public-private partnership with the directive to carry out basic science of relevance to drug discovery. The core mandate of the SGC is to determine 3D structures on a large scale and cost-effectively - targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets. SGC generates reagents and knowledge related to human proteins and proteins from human parasites. NCI’s Antibody Program partners with SGC to produce and characterize monocloncal antibodies to several proteins developed by this consortium.

The Virginia G. Piper Center for Personalized Diagnostics of the Biodesign Institute at Arizona State University

The Center for Personalized Diagnostics of the Biodesign Institute at Arizona State University applies Nucleic Acid Programmable Protein Arrays (NAPPA) technology to characterize monoclonal antibodies from CPTC. The Center for Personalized Diagnostics has taken the next step after the Human Genome Project by cloning all available human genes in a standard form that enables full-length, high throughput protein expression. By developing and applying new resources and technologies, this institute enables the study of proteins on a genome-wide scale using informatics and automation.

Ways to Partner with NCI-CPTC Antibody Characterization Program:

  • Protein Targets accepted approximately 1 - 2 times a year for antibody production and characterization through CPTC pipeline. All reagents made available to scientific community
  • Material Cooperative Research and Development Agreement (M-CRADA), interested parties can be submit at
  • Reagent Distribution: All CPTC affinity reagents (i.e. monoclonal antibodies) are distributed through non-exclusive license by MTA with NCI, CPTC program.